We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+11.53%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.52B
AUM Growth
-$155M
(-9.3%)
Cap. Flow
-$217M
Cap. Flow
% of AUM
-14.3%
Top 10 Holdings %
Top 10 Hldgs %
51.8%
Holding
41
New
7
Increased
5
Reduced
10
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$97.4M |
| 2 |
DaVita
DVA
|
+$44.6M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$44.6M |
| 4 |
DexCom
DXCM
|
+$44.2M |
| 5 |
Viasat
VSAT
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.9M |
| 2 |
AET
Aetna Inc
AET
|
+$61.4M |
| 3 |
AGN
Allergan plc
AGN
|
+$58.6M |
| 4 |
Merck
MRK
|
+$50.4M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.53% |
| 2 | Consumer Discretionary | 12.98% |
| 3 | Technology | 10.14% |
| 4 | Communication Services | 6.8% |
| 5 | Consumer Staples | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
GoDaddy
GDDY
$10.5B
| $102M | 6.76% |
2,036,589
| – | – |
|
|
2
Labcorp
LH
$25.1B
| $101M | 6.67% |
+737,001
| New | +$97.4M |
|
3
Caesars Entertainment
CZR
$6.04B
| $82.5M | 5.44% |
2,488,027
-207,105
| -8% | -$6.02M |
|
4
Nektar Therapeutics
NKTR
$2.37B
| $81.6M | 5.39% |
91,145
-60,499
| -40% | -$35.8M |
|
5
Post Holdings
POST
$4.17B
| $79.1M | 5.22% |
1,524,663
-247,539
| -14% | -$13.2M |
|
|
MDCO
6
DELISTED
Medicines Co
MDCO
| $76.8M | 5.07% |
2,808,954
| – | – |
|
7
Humana
HUM
$44.5B
| $75.5M | 4.98% |
304,424
+81,934
| +37% | +$20.2M |
|
8
Alnylam Pharmaceuticals
ALNY
$27.3B
| $63.6M | 4.19% |
500,219
+116,286
| +30% | +$14.6M |
|
9
Morgan Stanley
MS
$334B
| $63.5M | 4.19% |
1,210,359
| – | – |
|
10
Incyte
INCY
$24.3B
| $58.9M | 3.89% |
622,152
+306,890
| +97% | +$32.1M |
|
11
Armstrong World Industries
AWI
$7.31B
| $53M | 3.49% |
874,481
-376,975
| -30% | -$20.8M |
|
|
12
DaVita
DVA
$15.2B
| $52.3M | 3.45% |
+724,416
| New | +$44.6M |
|
13
MGM Resorts International
MGM
$11.4B
| $50.9M | 3.36% |
1,523,332
| – | – |
|
|
14
DexCom
DXCM
$31.8B
| $48.8M | 3.22% |
+3,403,100
| New | +$44.2M |
|
|
SGI
15
Somnigroup International
SGI
$14B
| $47.3M | 3.12% |
3,017,032
-1,160,316
| -28% | -$17.7M |
|
16
Atara Biotherapeutics
ATRA
$72.5M
| $47M | 3.1% |
103,944
+37,843
| +57% | +$14M |
|
|
WCG
17
DELISTED
Wellcare Health Plans, Inc.
WCG
| $46.3M | 3.06% |
+230,159
| New | +$44.6M |
|
|
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
| $44.9M | 2.96% |
2,021,979
-532,915
| -21% | -$13.1M |
|
19
Charter Communications
CHTR
$17.2B
| $39M | 2.57% |
116,109
| – | – |
|
|
EVHC
20
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $37.8M | 2.5% |
1,094,194
| – | – |
|
21
TG Therapeutics
TGTX
$8.01B
| $36M | 2.38% |
4,391,634
-903,410
| -17% | -$7.89M |
|
|
22
Viasat
VSAT
$10.6B
| $35.9M | 2.37% |
+479,356
| New | +$33.2M |
|
23
Liberty Broadband Class A
LBRDA
$4.87B
| $33.2M | 2.19% |
390,292
| – | – |
|
24
Meta Platforms (Facebook)
META
$1.39T
| $30.8M | 2.04% |
174,731
-51,597
| -23% | -$9.12M |
|
|
CTRA
25
DELISTED
Coterra Energy
CTRA
| $26.3M | 1.74% |
919,090
| – | – |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q4 2017 Portfolio in Review
As of Q4 2017, Bridger Management held 41 positions worth $1.52B, down 9.3% from $1.67B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Bridger Management withdrew a net $217M in Q4 2017, closing 8 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $77.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Bridger Management opened a new position in Labcorp worth $101M.
- Bridger Management's largest Q4 2017 buy was Labcorp: 737,001 shares worth $101M.
- Bridger Management added most to Incyte in Q4 2017, an estimated $32.1M increase.
- Bridger Management's biggest Q4 2017 reduction was Zimmer Biomet, cutting an estimated $39.6M.
- Bridger Management fully exited Alexion Pharmaceuticals in Q4 2017, selling an estimated $77.9M.
- Bridger Management's ten largest holdings make up 52% of its $1.52B portfolio in Q4 2017.
- Bridger Management opened 7 new positions and closed 8 in Q4 2017.
- Bridger Management's portfolio value fell 9.3% quarter-over-quarter to $1.52B.
Based on Bridger Management's 13F filing for Q4 2017, filed 14 Feb 2018.